Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Peter Voorhees, MD
Peter Voorhees, MD, is from the Levine Cancer Institute.
Articles by Peter Voorhees, MD
Panel Discusses Best Practices for Post-CAR-T Management with Local Health Care Teams
Thomas Martin, MD
Video Insights
|
May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
View More
Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, Infection
Thomas Martin, MD
Video Insights
|
May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
View More
Bispecific Versus CAR T-Cell Therapy for Myeloma, Bridging Therapy Needs for CAR-T
Thomas Martin, MD
Video Insights
|
May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
View More
Who Is the Right Patient for CAR-T Therapy?
Thomas Martin, MD
Video Insights
|
May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
View More
Frontline CAR-T Use and the 'Sweet Spot' for Treatment Sequencing
Thomas Martin, MD
Video Insights
|
May 5, 2023
The panel addresses the potential for frontline CAR-T use.
View More
Moving CAR-T Therapy Earlier in the Myeloma Treatment Course
Thomas Martin, MD
Video Insights
|
May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
View More
Is There an Ideal Space for Allogeneic CAR-T Products for Myeloma?
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
View More
Dual-Targeting, Allogeneic CARs Are Options to ‘Keep Myeloma on its Toes’
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
View More
A Look at the CAR-T Pipeline: ddBCMA and LUMMICAR
Thomas Martin, MD
Video Insights
|
May 4, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
View More
Ciltacabtagene Autoleucel and CARTITUDE Findings in Relapsed/Refractory Myeloma
Thomas Martin, MD
Video Insights
|
May 4, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
View More
Idecabtagene Vicleucel for Myeloma: KarMMa Study Results and Real-World Evidence
Thomas Martin, MD
Video Insights
|
May 5, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
View More
Spotlight on BCMA: A Major Target for Multiple Myeloma
Thomas Martin, MD
Video Insights
|
May 5, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
View More